Is plasma soluble CD36 associated with cardiovascular risk factors in early onset coronary artery disease patients?

Area of Science:

• Cardiovascular Research
• Biomarker Discovery
• Genetics

Background:

• Coronary artery disease (CAD) is a leading cause of mortality.
• Understanding novel biomarkers like soluble CD36 (sCD36) is crucial for early detection and management.
• The role of sCD36 and its genetic variations in early CAD remains largely unexplored.

Purpose of the Study:

• To investigate the relationship between plasma sCD36 concentrations and CD36 gene polymorphisms.
• To examine the association of sCD36 levels with clinical and echocardiographic parameters in patients with early CAD.
• To identify predictors of elevated sCD36 plasma levels.

Main Methods:

• Plasma sCD36 concentrations were quantified using ELISA kits.
• CD36 gene sequence variations (rs3173798, rs3211892, rs5956, rs141680676) were identified via DHPLC.
• Clinical data and echocardiographic measurements were collected and analyzed.

Main Results:

• sCD36 showed significant negative correlations with RBC count, hemoglobin, hematocrit, glucose, ApoB/ApoA1 ratio, weight, waist circumference, BMI, WHR, systolic blood pressure, and cardiac dimensions (LV, LA, RV).
• Positive correlations were observed between sCD36 and age, mean corpuscular volume, HDL-cholesterol, and ApoA1.
• Higher sCD36 levels were found in females, with female gender, older age, lower glucose, and lower RBC independently predicting higher sCD36.

Conclusions:

• Elevated sCD36 may offer protective effects against metabolic syndrome components in CAD patients.
• Higher sCD36 is associated with a reduced risk of left ventricular hypertrophy.
• Conversely, increased sCD36 concentration might indicate a potential risk factor for impaired left ventricle diastolic function.